Prognostic value of systemic inflammation and for patients with colorectal cancer cachexia
Journal of Cachexia, Sarcopenia and Muscle · 2023
DOI: 10.1002/jcsm.13358 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, 2023. Verfasst von Guo-Tian Ruan und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Surgery, Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Cachexia, Colorectal Neoplasms. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Key Research and Development Program, Beijing Municipal Science and Technology Commission, National Key Research and Development Program of China.
Abstract (Originalsprache)
Background
The development and progression of cancer cachexia are connected to systemic inflammation and physical performance. However, few relevant studies have reported the survival outcomes prediction of systemic inflammation and physical performance in patients with colorectal cancer (CRC) cachexia. This study investigated the prognostic prediction value of systemic inflammation and performance status in patients with CRC cachexia.
Methods
This multicentre cohort study prospectively collected 905 patients with CRC (58.3% males, 59.3 ± 11.5 years old). Cancer cachexia was diagnosed according to the 2011 Fearon Cachexia Diagnostic Consensus. The prognostic value of systematic inflammatory indicators was determined using the area under the curve, concordance index, and multivariate survival analysis. Performance status was evaluated with Eastern Coopertive Oncology Group performance score (ECOG‐PS). Survival data were analysed using univariate and multivariate Cox regression analyses.
Results
The area under the curve, concordance index and survival analysis showed that C‐reactive protein (CRP), lymphocyte to CRP ratio (LCR) and CRP to albumin ratio (CAR) were more stable and consistent with the survival of patients with CRC, both in non‐cachexia and cachexia populations. Among patients with CRC cachexia, high inflammation [low LCR, hazard ratio (HR) 95% confidence interval (95% CI) = 3.33 (2.08–5.32); high CAR, HR (95% CI) = 2.92 (1.88–4.55); high CRP, HR (95% CI) = 3.12 (2.08–4.67)] indicated a worse prognosis, compared with non‐cachexia patients [low LCR, HR (95% CI) = 2.28 (1.65–3.16); high CAR, HR (95% CI) = 2.36 (1.71–3.25); high CRP, HR (95% CI) = 2.58 (1.85–3.60)]. Similarly, among patients with CRC cachexia, high PS [ECOG‐PS 2, HR (95% CI) = 1.61 (1.04–2.50); ECOG‐PS 3/4, HR (95% CI) = 2.91 (1.69–5.00]) indicated a worse prognosis, compared with patients with CRC without cachexia [ECOG‐PS 2, HR (95% CI) = 1.28 (0.90–1.81); ECOG‐PS 3/4, HR (95% CI) = 2.41 (1.32–4.39]). Patients with CRC cachexia with an ECOG‐PS score of 2 or 3–4 and a high inflammation had a shorter median survival time, compared with patients with an ECOG‐PS score of 0/1 and a low inflammation.
Conclusions
The systemic inflammatory markers LCR, CAR and CRP have stable prognostic values in patients with CRC. The ECOG‐PS may be an independent risk factor for CRC. Combined evaluation of systemic inflammation and ECOG‐PS in patients with CRC cachexia could provide a simple survival prediction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastrointestinal Surgery, Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
- National Clinical Research Center for Geriatric Diseases, Xuanwu Hospital, Capital Medical University, Beijing, China.
- Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, China.
- Department of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
- Center of Gastrointestinal Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
- Yunnan University, Kunming, China.
ORCID-Profile: Han-Ping Shi
Förderung
- National Key Research and Development Program
- Beijing Municipal Science and Technology Commission
- National Key Research and Development Program of China
- Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park
Zitieren
APA
Ruan, G. T., Xie, H. L., Yuan, K. T., Lin, S. Q., Zhang, H. Y., Liu, C. A., Shi, J. Y., Ge, Y. Z., Song, M. M., Hu, C. L., Zhang, X. W., Liu, X. Y., Yang, M., Wang, K. H., Zheng, X., Chen, Y., Hu, W., Cong, M. H., Zhu, L. C., …, & Shi, H. P. (2023). Prognostic value of systemic inflammation and for patients with colorectal cancer cachexia. Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1002/jcsm.13358
Vancouver
Ruan GT, Xie HL, Yuan KT, Lin SQ, Zhang HY, Liu CA, et al. Prognostic value of systemic inflammation and for patients with colorectal cancer cachexia. Journal of Cachexia, Sarcopenia and Muscle. 2023. doi:10.1002/jcsm.13358
BibTeX
@article{Ruan2023,
author = {Ruan, Guo-Tian and Xie, Hai-Lun and Yuan, Kai-Tao and Lin, Shi-Qi and Zhang, He-Yang and Liu, Chen-An and Shi, Jin-Yu and Ge, Yi-Zhong and Song, Meng-Meng and Hu, Chun-Lei and Zhang, Xiao-Wei and Liu, Xiao-Yue and Yang, Ming and Wang, Kun-Hua and Zheng, Xin and Chen, Yue and Hu, Wen and Cong, Ming-Hua and Zhu, Li-Chen and Deng, Li and Shi, Han-Ping},
title = {Prognostic value of systemic inflammation and for patients with colorectal cancer cachexia},
journal = {Journal of Cachexia, Sarcopenia and Muscle},
year = {2023},
doi = {10.1002/jcsm.13358}
}
EUVIMED